Changes on venous diameter and leg perimeter with different clinical treatments for moderate chronic venous disease: evaluation using Duplex scanning and perimeter measurements.
OBJECTIVE
To evaluate changes on venous diameter and perimeter of lower limbs in chronic venous disorder (CVD) patients after different clinical treatments for four weeks.


METHODS
Fifty-two female patients classified as C2,s or C2,3,s (CEAP classification) were allocated consecutively in three groups: Cirkan (40 mg of the root extract of Ruscus aculeatus + 100 mg of flavonoid hesperidine methylchalcone + 200 mg of vitamin C per pill); elastic compression stockings (ECS) and no treatment (NT). Diameters were determined by duplex ultrasound and perimeter with Leg-O-Meter.


RESULTS
After treatment, Cirkan significantly decreased popliteal vein and great saphenous vein (GSV) diameters bilaterally and ECS decreased popliteal vein diameter bilaterally and GSV and varices only on the left limb. Perimeters changed only with ECS. Clinical scores changed between Cirkan x NT and ECS x Cirkan. Disability score varied for ECS x NT and Cirkan x NT. chi2 test detected different distribution frequency for C3 and C2 classes according to treatment: ECS (both limbs) and Cirkan (only left limb). Varices and anatomical scores did not change.


CONCLUSIONS
ECS emerges as the most effective clinical treatment tested but improvements with Cirkan on vein diameter and CEAP class were also observed. Clinical scores improved due to pain relief and edema reduction (ECS). These findings point to a positive effect of Cirkan, suggesting that venotonic drugs should be taken into account in the treatment of CVD.
Porto
C L Lascasas
CL
State University of Rio de Janeiro, Laboratório de Pesquisas em Microcirculação (LPM), Universidade do Estado do Rio de Janeiro, RJ, Brazil.
Milhomens
A L M
AL
Pires
C E
CE
Xavier
S Salles
SS
Sicuro
F
F
Bottino
D A
DA
Bouskela
E
E
D000328:Adult; D000886:Anthropometry / Q000295:instrumentation; D001205:Ascorbic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D001938:Brazil; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002908:Chronic Disease; D002918:Chymotrypsin / Q000009:adverse effects / Q000627:therapeutic use*; D004185:Disability Evaluation; D004338:Drug Combinations; D005260:Female; D006569:Hesperidin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D035002:Lower Extremity / Q000098:blood supply* / Q000473:pathology*; D008875:Middle Aged; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D010147:Pain Measurement; D010840:Phytosterols / Q000009:adverse effects / Q000627:therapeutic use*; D011152:Popliteal Vein / Q000000981:diagnostic imaging*; D012501:Saphenous Vein / Q000000981:diagnostic imaging*; D053828:Stockings, Compression; D013997:Time Factors; D016896:Treatment Outcome; D014357:Trypsin / Q000009:adverse effects / Q000627:therapeutic use*; D018616:Ultrasonography, Doppler, Duplex; D014652:Vascular Diseases / Q000150:complications / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*
D002317:Cardiovascular Agents; D004338:Drug Combinations; D010840:Phytosterols; C021980:hesperidine methylchalcone, ruscus aculeatus, vitamin C; D006569:Hesperidin; D002918:Chymotrypsin; D014357:Trypsin; D001205:Ascorbic Acid